

Investor Presentation

Future Facing Commodities Seminar

22 September 2021

Silex Systems Limited (Silex) (ASX: SLX) (OTCQX: SILXY) is pleased to provide a copy of its presentation for today's Future Facing Commodities Seminar being hosted by Shaw and Partners.

Authorised for release by the Silex Board of Directors.

Further information on the Company's activities can be found on the Silex website: <u>www.silex.com.au</u> or by contacting:

Michael Goldsworthy CEO/Managing Director T +61 2 9704 8888 E <u>investor.relations@silex.com.au</u> Julie Ducie CFO/Company Secretary T +61 2 9704 8888 E investor.relations@silex.com.au



Silex Systems Limited

Shaw and Partners: Future Facing Commodities Seminar

Dr Michael Goldsworthy **CEO/Managing Director** (ASX: SLX) (OTCQX: SILXY)

22 September 2021



www.silex.com.a

Forward Looking Statements and Risk Factors

About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY)

Silex Systems Limited ABN 69 003 372 067 (Silex) is a research and development company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company's technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee Global Laser Enrichment LLC (GLE) for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors including the satisfactory completion of the engineering scale-up program and uranium market conditions and therefore remains subject to associated risks.

Silex is also in the early stages of pursuing additional commercial applications of the SILEX technology, including the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing. The 'Zero-Spin Silicon' project remains dependent on the outcomes of the project and the viability of silicon quantum computing and is therefore at risk. The future of the SILEX technology is therefore uncertain and any plans for commercial deployment are speculative.

Additionally, Silex has an interest in a unique semiconductor technology known as 'cREO[®]' through its ownership of subsidiary Translucent Inc. The cREO[®] technology developed by Translucent has been acquired by IQE PIc based in the UK. IQE is progressing the cREO[®] technology towards commercial deployment for 5G mobile handset filter applications. The outcome of IQE's commercialisation program is also uncertain and remains subject to various technology and market risks.

Forward Looking Statements

The commercial potential of these technologies is currently unknown. Accordingly, no guarantees as to the future performance or competitiveness of these technologies can be made. The nature of the statements in this Presentation regarding the future of the SILEX technology, the cREO[®] technology and any associated commercial prospects are forward-looking and are subject to a number of variables, including but not limited to, unknown risks, contingencies and assumptions which may be beyond the control of Silex, its Directors and management. You should not place reliance on any forward-looking statements as actual results could be materially different from those expressed or implied by such forward looking statements as a result of various risk factors. Further, the forward-looking statements contained in this Presentation involve subjective judgement and analysis and are subject to change due to management's analysis of Silex's business, changes in industry trends, government policies and any new or unforeseen circumstances. The Company's management believes that there are reasonable grounds to make such statements as at the date of this Presentation. Silex does not intend, and is not obligated, to update the forward-looking statements except to the extent required by law or the ASX Listing. Rules.

Risk Factors

Risk factors that could affect future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to the impacts of the COVID-19 pandemic; the results of the SILEX uranium enrichment engineering development program; the market demand for natural uranium and enriched uranium; the outcome of the project to develop technology for the production of 'Zero-Spin Silicon' for the emerging technology of silicon-based quantum computing; the potential development of, or competition from alternative technologies; the potential for third party claims against the Company's ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the USA, Australia or elsewhere; results from IQE's commercialisation program and the market demand for cREO[®] products; decisions made or actions taken by the Company's commercialisation partners that could adversely affect technology commercialisation programs; and the outcomes of various strategies and projects undertaken by the Company.

Cover page image accreditation: Prof. Michelle Simmons team at UNSW/CQC2T demonstrated the fastest 2 qubit gate in silicon using atom qubits. Nature 571, 371 (2019) (Illustration by Tony Melov).



Silex is commercialising its unique SILEX laser enrichment technology for application to:



Silicon enrichment (silicon quantum computing)

Uranium production and enrichment (nuclear power)

Our strategy is focused on extracting maximum value from our core SILEX technology and expertise





Other potential markets (e.g. medical radioisotopes)

www.silex.com.au

SILEX Technology Commercialisation Overview



1. UxC 2022 estimates, UMO and EMO Q3, 2021

2. CSIRO, Growing Australia's Quantum Technology Industry, May 2020 (Note: raw materials such as ZS-Si would represent a very small fraction of this)



Model



Uranium Production and Enrichment for Nuclear Fuel



SILEX Uranium Production Opportunity

Global demand for Uranium is set to rise:

A significant potential uranium supply shortage is forecast

- Structural supply deficit could occur without a timely increase in production
- Demand could grow significantly as zero-emissions nuclear is embraced
- There are few low cost resources to supply increasing demand from the mid 2020's
- Uranium prices must keep increasing to provide stimulus for increased production

The Flagship Paducah uranium project – Global Laser Enrichment (GLE)

- Silex owns 51% equity interest in GLE with Cameco Corporation owning the balance of 49%
- GLE has an agreement with US DOE¹ to purchase tails inventories owned by the US Government
- GLE's Paducah project aims to enrich the tails using the SILEX technology to produce natural uranium

1. US Department of Energy





Paducah Uranium Production Opportunity

Target Commercial Operation Date

late 2020's

'Tier 1' Uranium Resource*

based on low cost and longevity of production

(Silex estimate of all-in cost < US\$25/lb)

Captures Value of Conversion

Product is UF₆ (current conversion value ~US\$10/lb)

* Per current estimates by Silex of project economics and longevity



Equivalent U₃O₈ **Production**


~ 5 million lbs per year for ~30 years

Potential to enrich further

From natural grade (0.7%) to LEU (up to 5%) & HALEU (up to 19.9%)

The Paducah Opportunity Value Chain

'Full Service' Nuclear Fuel Materials Concept



1. 2 MSWU is the estimated enrichment capacity to process ~5M lbs U_{nat} into LEU;

SWU – Separative Work Unit - is the unit of enrichment traded in the market;

2. US Nuclear Energy Institute estimates demand of 137 tons/yr by 2030 (2020 Letter to US DOE)



LEU Production ~2 MSWU¹/yr Enrichment

HALEU Production 100+ Tons/yr – by 2030²

Conventional Nuclear Power Reactors

Advanced Small Modular Reactors

Emerging Opportunity - Small Modular Reactors (SMR's)

- Several next generation SMR designs use High Assay Low Enriched Uranium (HALEU)
- SILEX technology may provide a flexible low cost alternative to produce HALEU for SMR's
- SMR's are modular, smaller size (50 MWe to 300 MWe) allows greater flexibility in deployment
- Designed for production-line manufacturing rather than conventional custom built capital projects
- SMR's anticipated to result in significant reduction in capital costs and shorter construction times
- Leading contenders anticipated to be introduced commercially in early 2030's in the US






ium (HALEU) ALEU for SMR's ibility in deployment m built capital projects rter construction times

SILEX Commercialisation and Royalty Agreement

- GLE holds exclusive worldwide license for use of SILEX laser technology for uranium
- License agreement includes US\$20 million in payments to Silex triggered by commercial development milestones:
 - US\$5 million: Commercial pilot demonstration (c.2025) 0
 - US\$5 million: Commencement of PLEF¹ EPC (c. 2027) 0
 - US\$10 million: PLEF commercial operations (c. late 2020's)
- Perpetual royalty of 7% (min.) on GLE's enrichment SWU revenues from use of SILEX for production of natural and enriched uranium
- Royalty and milestone payments are in addition to any equity-based distribution of profits payable from GLE's commercial operations (currently Silex holds 51% ownership)
- Cameco holds an option to purchase 26% of GLE equity from Silex at fair market value
- 1. PLEF: Paducah Laser Enrichment Facility



* Subject to technology development program outcomes, market conditions and other factors ** Engineering, Procurement and Construction (EPC)






Nuclear Power and the Nuclear Fuel Market Opportunity



Why Nuclear Power is so important to achieving net zero

Nuclear power is the only economic source of zero-emissions base load electricity




(LCOE = Levelised Cost Of Energy – all-in costs basis)



24/7 Reliability **Base Load Stability**

Clean Electricity for EV's and Hydrogen

US Uranium Market Outlook – Supply Shortage Forecast




Current uranium supplies will be insufficient to meet demand from 2023



Uranium Price – Price Recovery Underway

Uranium Long-Term Base Price Forecast



- UxC forecasts mid-case term uranium price ~\$50/lb by 2025 and ~\$65/lb by 2030
- Spot price now around \$50/lb up over ~250% since 2016 low (\$18/lb)
- Sprott Physical Uranium Trust (SPUT) intervention Q3 2021 driving current spot price recovery




-----Ux LT U3O8 High
-----Ux LT U3O8 Midpoint
-----Ux LT U3O8 Low
----Mid Long-Term Base
-----High Long-Term Base

---Composite LT Base

Paducah Opportunity helps address US Uranium Vulnerability

Uranium purchased for U.S. nuclear power reactors, 2010 - 2020

Million pounds U_3O_8 equivalent



Source: 2020 EIA Uranium Marketing Annual Report (Released May 2021)



US Imports ~90% (avg.) of Uranium purchased



Zero-Spin Silicon for Quantum Computing



SILEX Zero-Spin Silicon Opportunity

Global race to develop world's first Quantum Computers

- QC's will be 1000's of times more powerful than today's conventional computers
- QC will create new opportunities in medicine, AI, cybersecurity, finance, logistics etc
- Governments around the world and corporates such as Intel, Google, IBM, Microsoft are vying for leadership in QC development

Silicon Quantum Computing (QC) is a leading contender for QC technology


- Silicon QC is well placed to leverage off the existing silicon semiconductor industry
- Silicon QC requires highly enriched silicon, currently limited supply and expensive
- A reliable enriched silicon supply chain needs to be established to ensure commercial path
- With viable supply chain and timely commercialisation silicon could lead global QC efforts

The SILEX Zero-Spin Silicon (ZS-Si) production opportunity

- SILEX technology already proven capable of producing enriched silicon in the form of ZS-Si
- Current ZS-Si project aims to scale-up to pilot commercial production by end of 2022
- Project partners Silicon Quantum Computing (SQC) and UNSW Sydney are initial customers
- Silex aims to engage with other potential customers, including major semiconductor companies







SILEX Project for ZS-Si production gathering momentum

- Project partners SQC and UNSW part of the Federally funded 'CQC2T Centre of Excellence' a world leader in silicon-based QC technology development
- 3-year project cost ~\$8m (includes pilot plant capex) supported by \$3m Federal CRC-P funding grant and \$1.8m from SQC (including \$0.9m in advanced ZS-Si purchases)
- Project objective is to establish reliable and cost effective production of ZS-Si for potential sale to domestic and offshore consumers in the emerging global QC industry

3-stage project aims to produce ZS-Si in increasing purity and quantity:

- Stage 1: (Completed June 2020) Established 'proof-of-concept' for the SILEX process
- Stage 2: (Current) Validation of the SILEX technology and scalability for ZS-Si production
- Stage 3: Full technology demonstration for ZS-Si production at commercial pilot scale


ZS-Si Production Commercialisation Timeline*:

Stage 1 - completed		S	tage 2		Stage 3	
I	2020	I	2021	I	2022	I

* Subject to technology development program outcomes, market conditions and other factors.



ess uctic



ZS-Si Commercial Production* c. 2023 sales under SQC offtake agreement

2023

SILEX Zero-Spin Silicon Production Opportunity

Aim

establish a reliable and economic supply of high purity ZS-Si

Target Commercial Operation Date

2023

ZS-Si Target Purity

99.995% or higher



Production


Commercial pilot scale production up to 5 kgs per year, anticipated to increase over the next decade

Commercial Offtake Agreement with SQC

Other potential customers to be engaged



Summary



Summary



GLE JV (Silex 51% and Cameco 49%) aiming to demonstrate SILEX uranium enrichment technology at pilot commercial scale by the mid 2020's



GLE's path to market focused on the Paducah opportunity - a large, low cost uranium production project with additional potential for uranium enrichment to produce LEU and HALEU nuclear fuels



Long-term fundamentals for global growth in nuclear power remain positive, however a significant uranium supply deficit is looming in the absence of a timely increase in production



SILEX silicon enrichment technology being developed to produce Zero-Spin Silicon (ZS-Si) in support of global efforts to commercialise silicon quantum computing



Silex assessing several other applications of the SILEX technology, potentially in the fields of medical radioisotopes

As at 30 June 2021, the Company had net assets of ~\$22.1m, including ~\$14.1m in cash and approximately ~\$5.8m in IQE shares







Thank you

www.silex.com.au 22